Hjem › Marginalzone-lymfom
Marginalzone-lymfom kliniske forsøg rekrutterer i USA
56 studier for Marginalzone-lymfom rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- Durham, NC12 studier
- New York City, NY11 studier
- Seattle, WA9 studier
- Milwaukee, WI9 studier
- Boston, MA9 studier
- Baldwin Park, CA9 studier
- Edison, NJ8 studier
- Rochester, MN8 studier
- Columbus, OH8 studier
- Houston, TX8 studier
- Miami, FL7 studier
- Nashville, TN7 studier
- Denver, CO7 studier
- Jacksonville, FL6 studier
- St. Louis, MO6 studier
- Salt Lake City, UT6 studier
- Portland, OR5 studier
- Queens, NY5 studier
- Greenburgh, NY5 studier
- Dallas, TX5 studier
- Chicago, IL5 studier
- Cleveland, OH5 studier
- Atlanta, GA5 studier
- Washington, DC5 studier
- Staten Island, NY4 studier
- Minneapolis, MN4 studier
- New Rochelle, NY4 studier
- Buffalo, NY4 studier
- Los Angeles, CA4 studier
- Tampa, FL4 studier
- Cincinnati, OH4 studier
- Philadelphia, PA4 studier
- Richmond, VA3 studier
- East Norwalk, CT3 studier
- Ann Arbor, MI3 studier
- Providence, RI3 studier
- Mountain View, CA3 studier
- San Francisco, CA3 studier
- Cedar Rapids, IA3 studier
- Scottsdale, AZ3 studier
Efter delstat
- Arizona5 studier
- Californien18 studier
- Colorado8 studier
- Connecticut4 studier
- Florida15 studier
- Georgia6 studier
- Illinois6 studier
- Iowa4 studier
- Kansas3 studier
- Maryland6 studier
- Massachusetts12 studier
- Michigan5 studier
- Minnesota12 studier
- Missouri6 studier
- New Jersey9 studier
- New York16 studier
- North Carolina14 studier
- Ohio13 studier
- Oregon5 studier
- Pennsylvania5 studier
- Rhode Island3 studier
- Tennessee8 studier
- Texas12 studier
- Utah6 studier
- Virginia4 studier
- Washington10 studier
- Wisconsin10 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07763210A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07231952Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT07583810A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05006716Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RekruttererObservationsstudie
Alder 18 til 110 · Alle køn · Opdateret 28. sep. 2026 · NCT00923507Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06350318Epco, Zanu, Ritux for R/R FL or MZL
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06563596Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT04840602A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07101328Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 21. sep. 2026 · NCT05296070Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT07225439A Study of ARC-02 in B-cell NHL
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 26. aug. 2026 · NCT07691606Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT04792502A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 14. aug. 2026 · NCT06149286AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 12. aug. 2026 · NCT06340737HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 12. aug. 2026 · NCT06792825Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruttererFase 1/2
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RekruttererFase 1
Alder 18 til 81 · Alle køn · Opdateret 6. aug. 2026 · NCT05990465A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 31. jul. 2026 · NCT06708897A Study of APG-3288 in Relapsed/Refractory Blood Cancers
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. jul. 2026 · NCT07424833This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 24. jul. 2026 · NCT07121946Allo HSCT Using RIC and PTCy for Hematological Diseases
RekruttererFase 2
Op til 75 år · Alle køn · Opdateret 6. jul. 2026 · NCT05805605A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. jul. 2026 · NCT05131022Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 1. jul. 2026 · NCT06860880Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. jun. 2026 · NCT06905509Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.